When combined with a therapeutic agent such as rAd-p53, it may prolong local exposure and enhance adenovirus-mediated transduction of tumor cells, leading to higher exogenous p53 expression and potentially improved clinical outcomes (23). This evidence concerns the gene TP53 and neoplasm.